Jade Biosciences (JBIO) Net Income towards Common Stockholders (2020 - 2026)

Jade Biosciences has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$40.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 5.76% year-over-year to -$40.4 million; the trailing twelve-month figure through Mar 2026 stood at -$123.4 million (down 22.96% YoY), and the FY2025 full-year result was $178000.0, up 100.26% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$40.4 million, down from -$31.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $45.2 million in Q4 2023, with the low at -$47.0 million in Q4 2024.
• Historically, Net Income towards Common Stockholders has averaged -$15.6 million across 5 years, with a median of -$19.0 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 434.28% — and 2025, when it plunged 4254.03%.
• Jade Biosciences' Net Income towards Common Stockholders stood at $27.5 million in 2022, then soared by 64.51% to $45.2 million in 2023, then tumbled by 203.89% to -$47.0 million in 2024, then soared by 32.11% to -$31.9 million in 2025, then retreated by 26.57% to -$40.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$40.4 million (Q1 2026), -$31.9 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.